|
OVERVIEW
WHO Tuberculosis Fact Sheet - World Health Organization TB fact sheet - revised March 2007
TREATMENT
CDC MMWR Treatment of Tuberculosis June 2003 (full report )
- Table 2: Drug regimens for culture-positive pulmonary tuberculosis caused by drug-susceptible organisms.
- Table 3: Doses of antituberculous drugs in adults and children
- Table 12: Clinically significant drug-drug interactions involving rifamycins
Tuberculosis Treatment in Resource-Limited Settings in the AETC Clinical Manual for Management of the HIV-Infected Adult 2006 ed.
CDC MMWR Prevention and Treatment of Tuberculosis Among Patients Infected with Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations - 78-page updated guidelines - Oct 1998
TB/HIV Drug Interactions (full report)
- Table 1: CDC recommendations for co-administering protease inhibitors and non-nucleoside reverse transcriptase inhibitors with RIFAMPIN - 2004.
- Table 2: CDC recommendations for co-administering protease inhibitors and non-nucleoside reverse transcriptase inhibitors with RIFABUTIN - 2004.
(top of page)
MDR TB & XDR TB
WHO - Drug- and multidrug-resistant Tuberculosis (MDR-TB) - Frequently Asked Questions
WHO Report: Anti-tuberculosis drug resistance in the world - E-book containing results of a survey conducted in 77 different countries/geographical settings, between 1999 and 2002 by WHO and the International Union Against Tuberculosis and Lung Disease Global Project - 2004
Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs- Worldwide 2002-2004.
CDC report of the emergence of XDR TB globally. XDR TB is defined as TB resistant to rifampicin and isoniazid, as well as any fluoroquinolone and at least one injectable anti-TB drug. A recent outbreak of XDR TB in an HIV-infected population in South Africa had an alarmingly high mortality (52 out of 53 patients). March 2006.
Investigation of U.S. Traveler with XDR TB - CDC website with information on XDR-TB, relevant press releases and details about the event.
(top of page)
PROGRAMMATIC INTERVENTIONS
WHO DOTS Guidelines - DOTS is the internationally-recommended TB control strategy and combines five essential elements - 2002
WHO TB Treatment Guidelines - 110-page e-book of WHO guidelines for treatment of TB for international programmes - 2003
Guidance for national tuberculosis programs on the management of tuberculosis in children.
WHO guidelines for TB in children including recommendations on treatment, diagnosis, contact screening and BCG vaccination. 50 pages. 2006.
Tuberculosis infection control in the era of expanding HIV care and treatment.
WHO guidelines to minimize the risk of TB transmission in facilities that provide care to HIV-infected persons or in institutions such as prisons and rehabilitation centers where the prevalence of HIV is high. 43 pages. 2006.
The Stop TB Strategy.
WHO strategy for national TB programs and collaborators with emphasis on the following components: DOTS, HIV/TB, MDRTB, health care system infrastructure, private/public partnerships, community involvement, and research.
(top of page)
RESEARCH
HINARI (Health InterNetwork Access to Research Initiative) - The HINARI program, set up by WHO together with major publishers, enables developing countries to gain access to one of the world's largest collections of biomedical and health literature.
(Return to Resource Topics Menu)
|
